Ginsenoside RG3 inhibits epithelial-mesenchymal transition of gallbladder cancer cells through PI3K/AKT/mTOR signaling pathway

doi:10.16139/j.1007-9610.2026.01.12

Abstract

Abstract:

Objective To explore the specific mechanism of Ginsenoside Rg3 inhibiting gallbladder cancer (GBC)cells. Methods Cell counting kit-8(CCK-8) assay was used to examine the effect of Ginsenoside Rg3 on the viability of GBC cells. The effect of Ginsenoside Rg3 on the migration and invasion of gallbladder cancer cells was verified by cell scratch assay and Transwell assay. Western blot was used to verify the effect of Ginsenoside Rg3 on epithelial-mesenchymal transition (EMT)-related proteins and phosphatidylinositol 3-kinase / protein kinase B (AKT) / mammalian target of rapamycin [PI3K/PKB(AKT)/mTOR] signaling pathway-related proteins. Results Ginsenoside Rg3 significantly inhibited the viability of GBC cells. Ginsenoside Rg3 significantly inhibited the rate of cell migration and the number of cells passing through the Transwell assay. Western blot showed that Ginsenoside Rg3 could significantly reduce the level of phosphorylated PI3K/AKT/mTOR protein, increase the expression level of E-cadherin, and inhibit the expression levels of N-cadherin and vimentin in gallbladder cancer cells, and finally inhibit the EMT process. Conclusions Ginsenoside RG3 inhibits the activity of gallbladder cancer cells, also suppresses the EMT process by regulating the PI3K/AKT/mTOR signaling pathway and inhibits the migration and invasion of gallbladder cancer cells.

Key words: Gallbladder cancer, Signaling pathway, Epithelial-mesenchymal transition(EMT), Ginsenoside Rg3

CLC Number:

R735.8

ZHOU Xin, WANG Lubing, ZHANG Bo. Ginsenoside RG3 inhibits epithelial-mesenchymal transition of gallbladder cancer cells through PI3K/AKT/mTOR signaling pathway[J]. Journal of Surgery Concepts & Practice, 2026, 31(01): 70-76.

Figures/Tables 5

Fig 1

Tab1

Fig 2

Fig 3

Fig 4

References 20

[1]	CHEE M, WU A, FONG K Y, et al. Robotic, laparoscopic and open surgery for gallbladder cancer: a systematic review and network meta-analysis[J]. Surg Endosc, 2024, 38(9):4846-4857. doi: 10.1007/s00464-024-11162-6 pmid: 39148006
[2]	HE H, CHEN S, YU Y, et al. Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer[J]. Gut, 2024, 73(9):1529-1542. doi: 10.1136/gutjnl-2023-331773 pmid: 38719336
[3]	ZHANG R, LI L, LI H, et al. Ginsenoside 20(S)-Rg3 reduces KIF20A expression and promotes CDC25A proteasomal degradation in epithelial ovarian cancer[J]. J Ginseng Res, 2024, 48(1):40-51. doi: 10.1016/j.jgr.2023.06.008 URL
[4]	WU L, BAI L, DAI W, et al. Ginsenoside Rg3: a review of its anticancer mechanisms and potential therapeutic applications[J]. Curr Top Med Chem, 2024, 24(10):869-884. doi: 10.2174/0115680266283661240226052054 pmid: 38441023
[5]	ZENG X, LIU S, YANG H, et al. Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1alpha/VEGF and EMT signalling pathways[J]. J Pharm Pharmacol, 2023, 75(11):1405-1417. doi: 10.1093/jpp/rgad070 URL
[6]	张英, 王学谦, 刘浩, 等. 参一胶囊联合化疗改善晚期非小细胞肺癌患者预后的多中心大样本随机临床研究[J]. 中华肿瘤杂志, 2018, 40(4):295-299.
	ZHANG Y, WANG X Q, LIU H, et al. A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy[J]. Chin J Oncol, 2018, 40(4):295-299.
[7]	LEE Y, PARK A, PARK Y J, et al. Ginsenoside 20(R)-Rg3 enhances natural killer cell activity by increasing activating receptor expression through the MAPK/ERK signaling pathway[J]. Int Immunopharmacol, 2022, 107:108618. doi: 10.1016/j.intimp.2022.108618 URL
[8]	WANG X, HE R, GENG L, et al. Ginsenoside Rg3 alleviates cisplatin resistance of gastric cancer cells through inhibiting SOX2 and the PI3K/Akt/mTOR signaling axis by up-regulating miR-429[J]. Front Genet, 2022, 13:823182. doi: 10.3389/fgene.2022.823182 URL
[9]	ZHOU B, YAN Z, LIU R, et al. Prospective study of transcatheter arterial chemoembolization (TACE) with ginsenoside Rg3 versus TACE alone for the treatment of patients with advanced hepatocellular carcinoma[J]. Radiology, 2016, 280(2):630-639. doi: 10.1148/radiol.2016150719 URL
[10]	MANFIOLETTI G, FEDELE M. Epithelial-mesenchymal transition (EMT)[J]. Int J Mol Sci, 2023, 24(14):11386. doi: 10.3390/ijms241411386 URL
[11]	EBRAHIMI N, HAKIMZADEH A, BOZORGMAND F, et al. Role of non-coding RNAs as new therapeutic targets in regulating the EMT and apoptosis in metastatic gastric and colorectal cancers[J]. Cell Cycle, 2023, 22(20):2302-2323. doi: 10.1080/15384101.2023.2286804 URL
[12]	ROUPAKIA E, CHAVDOULA E, KARPATHIOU G, et al. Canonical NF-kappaB promotes lung epithelial cell tumour growth by downregulating the metastasis suppressor CD82 and enhancing epithelial-to-mesenchymal cell transition[J]. Cancers (Basel), 2021, 13(17):4302. doi: 10.3390/cancers13174302 URL
[13]	TU M, YIN X, ZHUANG W, et al. NSG1 promotes glycolytic metabolism to enhance esophageal squamous cell carcinoma EMT process by upregulating TGF-beta[J]. Cell Death Discov, 2023, 9(1):391. doi: 10.1038/s41420-023-01694-6
[14]	CHEN E X, HU S C, XU J Q, et al. Suppression of GATA3 promotes epithelial-mesenchymal transition and simultaneous cellular senescence in human extravillous trophoblasts[J]. Biochim Biophys Acta Mol Cell Res, 2024, 1871(7):119768. doi: 10.1016/j.bbamcr.2024.119768 URL
[15]	MAO X, JIN Y, FENG T, et al. Ginsenoside Rg3 inhibits the growth of osteosarcoma and attenuates metastasis through the Wnt/Beta-Catenin and EMT signaling pathway[J]. Evid Based Complement Alternat Med, 2020, 2020:6065124. doi: 10.1155/ecam.v2020.1 URL
[16]	WANG S, CHENG Z, CUI Y, et al. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway[J]. J Transl Med, 2023, 21(1):819. doi: 10.1186/s12967-023-04703-5
[17]	PANNEERPANDIAN P, GANESAN K. PI3K/AKT/mTOR inhibitors as potential extracellular matrix modulators for targeting EMT subtype gastric tumors[J]. Med Oncol, 2023, 40(4):120. doi: 10.1007/s12032-023-01984-0 pmid: 36934368
[18]	ANG H L, MOHAN C D, SHANMUGAM M K, et al. Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds[J]. Med Res Rev, 2023, 43(4):1141-1200. doi: 10.1002/med.v43.4 URL
[19]	HU J, LI G, LIU Z, et al. Bicarbonate transporter SLC4A7 promotes EMT and metastasis of HNSCC by activating the PI3K/AKT/mTOR signaling pathway[J]. Mol Carcinog, 2023, 62(5):628-640. doi: 10.1002/mc.v62.5 URL
[20]	LUO M, CHEN Y J, XIE Y, et al. Dickkopf-related protein 1/cytoskeleton-associated protein 4 signaling activation by Helicobacter pylori-induced activator protein-1 promotes gastric tumorigenesis via the PI3K/AKT/mTOR pathway[J]. World J Gastroenterol, 2022, 28(47):6769-6787. doi: 10.3748/wjg.v28.i47.6769 URL

Cell line	Time	Concentration (µM)	Cell viability (%)
GBC-SD	24 h	0	100
		50	79.25±2.09^**
		100	62.31±2.53^****
		150	39.34±2.11^****
		200	20.07±2.55^****
	48 h	0	100
		50	69.03±7.55^****
		100	52.66±3.22^****
		150	41.66±2.00^****
		200	11.61±3.06^****
NOZ	24 h	0	100
		50	77.32±1.53^***
		100	62.33±2.51^***
		150	41.03±2.01^****
		200	20.29±1.51^****
	48 h	0	100
		50	67.00±3.02^***
		100	51.02±1.07^****
		150	27.33±2.09^****
		200	8.35±2.59^***